Evidence map›Paper›PMID 22307032›Full record

ArticleGastroenterology2012

Hepatic cannabinoid receptor-1 mediates diet-induced insulin resistance via inhibition of insulin signaling and clearance in mice.

Jie Liu, Liang Zhou, Keming Xiong, Grzegorz Godlewski, Bani Mukhopadhyay, Joseph Tam, Shi Yin, Peter Gao, Xin Shan, James Pickel and 5 more

Open access · bronzeAbstract read
In one paragraph

Article in Gastroenterology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 102 papers.

0numbers the graph read from it
0cells of the map it votes in
102citing papers in PubMed
15.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

102 citing papers in PubMed, 171 citations in OpenAlex.

  1. Trial
  2. GPCR Biased Signaling in Metabolism.Handbook of experimental pharmacology · 2026
    Review
  3. Genetic Tools in Rodents to Study Cannabinoid Functions.Current topics in behavioral neurosciences · 2026
    Review
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. The Role of the Endocannabinoid System in Binge Eating Disorder.International journal of molecular sciences · 2023
    Review
  10. Review
  11. Review
  12. Hepatic targeting of the centrally active cannabinoid 1 receptor (CBJournal of controlled release : official journal of the Controlled Release Society · 2023
    Article
  13. Article
  14. Article
  15. Review
  16. Review
  17. Article
  18. Article
  19. Review
  20. Article

42 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

15 authors at 4 institutions in 2 countries.

Jie LiuLaboratory of Physiologic Studies, National Institute on Alcohol Abuse and Alcoholism, Bethesda, Maryland 20892-9413, USA. jiel@mail.nih.gov
Liang Zhou
Keming Xiong
Grzegorz Godlewski
Bani Mukhopadhyay
Joseph Tam
Shi Yin
Peter Gao
Xin Shan
James Pickel
Ramon Bataller
James O'Hare
Thomas Scherer
Christoph Buettner
George Kunos
National Institute on Alcohol Abuse and Alcoholism · USIcahn School of Medicine at Mount Sinai · USConsorci Institut D'Investigacions Biomediques August Pi I Sunyer · ESNational Institute of Mental Health · US

Funding

Transgenic Resources for Neuroscience ResearchZICMH002901 · NIMH · NATIONAL INSTITUTE OF MENTAL HEALTH · PI AMARA, SUSAN · 2009 to 2025
$36.5M
Endocannabinoids And Energy HomeostasisZIAAA000350 · NIAAA · NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM · PI KUNOS, GEORGE · 2009 to 2025
$28.4M
Regulation of Adipose Tissue Metabolism by Central Insulin and LeptinR01DK083658 · NIDDK · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI BUETTNER, CHRISTOPH · 2009 to 2013
$1.9M
Intramural NIH HHS ZIA AA000350NIDDK NIH HHS R01 DK083658
6 · The paper itself

Abstract

BACKGROUND &

aimsObesity-related insulin resistance contributes to cardiovascular disease. Cannabinoid receptor-1 (CB(1)) blockade improves insulin sensitivity in obese animals and people, suggesting endocannabinoid involvement. We explored the role of hepatic CB(1) in insulin resistance and inhibition of insulin signaling pathways.

methodsWild-type mice and mice with disruption of CB(1) (CB(1)(-/-) mice) or with hepatocyte-specific deletion or transgenic overexpression of CB(1) were maintained on regular chow or a high-fat diet (HFD) to induce obesity and insulin resistance. Hyperinsulinemic-euglycemic clamp analysis was used to analyze the role of the liver and hepatic CB(1) in HFD-induced insulin resistance. The cellular mechanisms of insulin resistance were analyzed in mouse and human isolated hepatocytes using small interfering or short hairpin RNAs and lentiviral knockdown of gene expression.

resultsThe HFD induced hepatic insulin resistance in wild-type mice, but not in CB(1)(-/-) mice or mice with hepatocyte-specific deletion of CB(1). CB(1)(-/-) mice that overexpressed CB(1) specifically in hepatocytes became hyperinsulinemic as a result of reduced insulin clearance due to down-regulation of the insulin-degrading enzyme. However, they had increased hepatic glucose production due to increased glycogenolysis, indicating hepatic insulin resistance; this was further increased by the HFD. In mice with hepatocytes that express CB(1), the HFD or CB(1) activation induced the endoplasmic reticulum stress response via activation of the Bip-PERK-eIF2α protein translation pathway. In hepatocytes isolated from human or mouse liver, CB(1) activation caused endoplasmic reticulum stress-dependent suppression of insulin-induced phosphorylation of akt-2 via phosphorylation of IRS1 at serine-307 and by inducing the expression of the serine and threonine phosphatase Phlpp1. Expression of CB(1) was up-regulated in samples from patients with nonalcoholic fatty liver disease.

conclusionsEndocannabinoids contribute to diet-induced insulin resistance in mice via hepatic CB(1)-mediated inhibition of insulin signaling and clearance.

Indexed as

Insulin ResistanceSignal TransductionAnimalsArachidonic AcidsDiet, High-FatEndocannabinoidsEndoplasmic Reticulum StressFatty LiverGlucose IntoleranceHumansInsulinLiverMaleMetabolic Clearance RateMiceMice, Inbred C57BLAKT2 protein, humananandamideArachidonic AcidsEndocannabinoidsInsulinPolyunsaturated AlkamidesProto-Oncogene Proteins c-aktReceptor, Cannabinoid, CB1

Identifiers

PMID22307032
PMCPMC3482511
OpenAlexW2115860672

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.